GLATIRAMER vs SIPONIMOD

Compare GLATIRAMER (Glatiramer Acetate) and SIPONIMOD (MAYZENT) — clinical data, side effects, and patient experiences.

GLATIRAMER

Glatiramer Acetate · Other

How it works

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act...

Approved for

1 INDICATIONS AND USAGE Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

SubcutaneousTablet

SIPONIMOD

MAYZENT, Mayzent · S1P Receptor Modulator

How it works

12.1 Mechanism of Action Siponimod is an S1P receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5. Siponimod blocks the capacity of lymphocytes to egress...

Approved for

1 INDICATIONS AND USAGE MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

OralTablet

Quick Comparison

GLATIRAMERSIPONIMOD

Drug Class

Other

S1P Receptor Modulator

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

GLATIRAMER

Injection Site Pain

>10%

Drug Not Working

1-10%

Injection Site Reaction

1-10%

Fatigue

1-10%

Shortness of Breath

1-10%

Falls

1-10%

Nausea

0.1-1%

Dizziness

0.1-1%

SIPONIMOD

Fatigue

>10%

Headache

>10%

Dizziness

1-10%

Falls

1-10%

Drug Not Working

1-10%

Nausea

1-10%

UTI

0.1-1%

Weakness

0.1-1%

FDA Warnings

GLATIRAMER

5 WARNINGS AND PRECAUTIONS • Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting ( 5
6 ) • Glatiramer Acetate Products and Administration Errors: Using an optional autoinjector that is not compatible for use with Mylan’s glatiramer acetate injection may increase the risk for medication errors, such as dose omission or administration of a partial dose
1 Anaphylactic Reactions Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection [see Adverse Reactions (6
Glatiramer acetate injection is contraindicated in patients with a history of hypersensitivity reactions to glatiramer acetate injection, including anaphylaxis [see Contraindications (4) ]

SIPONIMOD

5 WARNINGS AND PRECAUTIONS Infections: MAYZENT may increase the risk
2 ) Macular Edema: Increases the risk of macular edema
Diabetes mellitus and uveitis increase the risk
8 ) Fetal Risk: Women of childbearing potential should use effective contraception during and for 10 days after stopping MAYZENT

Clinical Trial Data

No head-to-head clinical studies found for GLATIRAMER vs SIPONIMOD.

GLATIRAMER vs SIPONIMOD: What You Should Know

Key Differences

GLATIRAMER is a Other, while SIPONIMOD belongs to the S1P Receptor Modulator class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. GLATIRAMER is administered via Subcutaneous, whereas SIPONIMOD uses Oral. Route of administration can affect onset of action and patient adherence.

Shared Indications

Both medications are approved for to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, to include clinically isolated syndrome. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.

Safety Considerations

GLATIRAMER carries 4 FDA warnings. SIPONIMOD carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

DIMETHYL FUMARATE vs GLATIRAMER→DIMETHYL FUMARATE vs SIPONIMOD→FINGOLIMOD vs GLATIRAMER→FINGOLIMOD vs SIPONIMOD→GLATIRAMER vs TERIFLUNOMIDE→SIPONIMOD vs TERIFLUNOMIDE→

Loading comparison data...

GLATIRAMER vs SIPONIMOD

Compare GLATIRAMER (Glatiramer Acetate) and SIPONIMOD (MAYZENT) — clinical data, side effects, and patient experiences.

GLATIRAMER

Glatiramer Acetate · Other

How it works

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act...

Approved for

1 INDICATIONS AND USAGE Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

SubcutaneousTablet

SIPONIMOD

MAYZENT, Mayzent · S1P Receptor Modulator

How it works

12.1 Mechanism of Action Siponimod is an S1P receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5. Siponimod blocks the capacity of lymphocytes to egress...

Approved for

1 INDICATIONS AND USAGE MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

OralTablet

Quick Comparison

GLATIRAMERSIPONIMOD

Drug Class

Other

S1P Receptor Modulator

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

GLATIRAMER

Injection Site Pain

>10%

Drug Not Working

1-10%

Injection Site Reaction

1-10%

Fatigue

1-10%

Shortness of Breath

1-10%

Falls

1-10%

Nausea

0.1-1%

Dizziness

0.1-1%

SIPONIMOD

Fatigue

>10%

Headache

>10%

Dizziness

1-10%

Falls

1-10%

Drug Not Working

1-10%

Nausea

1-10%

UTI

0.1-1%

Weakness

0.1-1%

FDA Warnings

GLATIRAMER

5 WARNINGS AND PRECAUTIONS • Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting ( 5
6 ) • Glatiramer Acetate Products and Administration Errors: Using an optional autoinjector that is not compatible for use with Mylan’s glatiramer acetate injection may increase the risk for medication errors, such as dose omission or administration of a partial dose
1 Anaphylactic Reactions Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection [see Adverse Reactions (6
Glatiramer acetate injection is contraindicated in patients with a history of hypersensitivity reactions to glatiramer acetate injection, including anaphylaxis [see Contraindications (4) ]

SIPONIMOD

5 WARNINGS AND PRECAUTIONS Infections: MAYZENT may increase the risk
2 ) Macular Edema: Increases the risk of macular edema
Diabetes mellitus and uveitis increase the risk
8 ) Fetal Risk: Women of childbearing potential should use effective contraception during and for 10 days after stopping MAYZENT

Clinical Trial Data

No head-to-head clinical studies found for GLATIRAMER vs SIPONIMOD.

GLATIRAMER vs SIPONIMOD: What You Should Know

Key Differences

Shared Indications

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.